SynAct Pharma AB Company Description

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden.

The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency.

It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.

SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden.

SynAct Pharma AB

Country	Sweden
Founded	2012
Industry	Biological Products, Except Diagnostic Substances
Employees	6
CEO	Jeppe Ovlesen

Contact Details

Address: ScheelevAegen 2 Lund, 223 63 Sweden
Phone	46 1 03 00 10 23
Website	synactpharma.com

Stock Details

Ticker Symbol	8F8
Exchange	Frankfurt Stock Exchange
Fiscal Year	January - December
Reporting Currency	SEK
SIC Code	2836

Key Executives

Name	Position
Jeppe Ovlesen	Chief Executive Officer
Bjorn Westberg	Chief Financial Officer
Thomas Boesen	Chief Operating Officer